RE:RE:RE:RE:RE:Why Ranbaxy? Galephar Pharmaceutical Research
Cipher has established a strong collaborative partnership with Galephar, a Puerto Rico-based company with oral and pulmonary drug delivery technology, formulation, manufacturing and quality control expertise. Galephar typically works with unique formulations of well-known, active pharmaceutical ingredients. The company's principal owners are Philippe Baudier, President, and Arthur Deboeck, Vice President and General Manager. Their experience in drug delivery and manufacturing R&D spans three decades with a singular focus on galenical research, which is the process of improving the delivery of medications into the body.
Ranbaxy has the right to market, sell and distribute CIP-ISOTRETINOIN in the United States. From reading off their website it is a three way deal in the US, don't know the legal ramifications on the deal other than in my opinion it is rather poor. 7.5% of sales of Absorica
Innocutis is the million dollar question we have to wait a couple years and see.